After two failed late-stage clinical trials, Lundbeck has called it quits on its experimental Alzheimer's drug.
The Denmark-based drugmaker said the trials for its idalopirdine "do not demonstrate efficacy to support a regulatory submission."
The 5-HT6 antagonist was aimed at treating symptoms of the brain disorder, rather than halting progression of the underlying disease. U.S.-based rival Axovant Sciences is developing similar 5-HT6 antagonist drug called intepirdine.
Read the Reuters coverage